Equities research analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will report ($0.06) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for AVEO Pharmaceuticals’ earnings. AVEO Pharmaceuticals posted earnings per share of ($0.12) during the same quarter last year, which indicates a positive year over year growth rate of 50%. The business is expected to issue its next earnings results on Thursday, May 3rd.
On average, analysts expect that AVEO Pharmaceuticals will report full year earnings of ($0.25) per share for the current financial year, with EPS estimates ranging from ($0.26) to ($0.24). For the next financial year, analysts anticipate that the company will post earnings of ($0.17) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover AVEO Pharmaceuticals.
AVEO has been the subject of several recent analyst reports. Zacks Investment Research cut shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, December 6th. BidaskClub cut shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th. Finally, B. Riley restated a “buy” rating and set a $5.00 price objective on shares of AVEO Pharmaceuticals in a research report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. AVEO Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $4.05.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $2.72 on Friday. AVEO Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $4.24. The stock has a market cap of $321.83, a PE ratio of -4.46 and a beta of 1.38. The company has a debt-to-equity ratio of -0.45, a quick ratio of 2.33 and a current ratio of 1.56.
Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in AVEO Pharmaceuticals by 48.6% during the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock worth $7,884,000 after buying an additional 1,162,232 shares during the period. Emory University purchased a new position in AVEO Pharmaceuticals during the fourth quarter worth about $1,682,000. Essex Investment Management Co. LLC boosted its stake in AVEO Pharmaceuticals by 34.1% during the fourth quarter. Essex Investment Management Co. LLC now owns 202,004 shares of the biopharmaceutical company’s stock worth $564,000 after buying an additional 51,384 shares during the period. X Square Capital LLC purchased a new position in AVEO Pharmaceuticals during the fourth quarter worth about $557,000. Finally, Prosight Management LP purchased a new position in AVEO Pharmaceuticals during the fourth quarter worth about $2,951,000. 51.82% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “-$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/0-06-eps-expected-for-aveo-pharmaceuticals-inc-aveo-this-quarter.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.